Efficacy and safety of switching to long-acting cabotegravir + rilpivirine versus continuing bictegravir/emtricitabine/tenofovir alafenamide in Japanese participants: 12-month results from the phase 3b randomized SOLAR trial

Authors:

Abstract
No abstract available
Funding Information
  • ViiV Healthcare

This publication has 7 references indexed in Scilit: